Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Amerisource Faces Government Source: CEO Disputes Report Of Inquiry

  • News

Executive Summary

An investigation of AmerisourceBergen's role in facilitating drug diversion appears to focus on an institutional pharmacy that Amerisource dropped as a client in 2000, CEO David Yost said

You may also be interested in...



Rx Wholesalers Responding To Subpoenas On Deals With “Secondary” Market

AmerisourceBergen, Cardinal Health and McKesson are responding to subpoenas from the New York Attorney General's office regarding their use of "secondary" wholesalers as a source of pharmaceuticals

Rx Wholesalers Responding To Subpoenas On Deals With “Secondary” Market

AmerisourceBergen, Cardinal Health and McKesson are responding to subpoenas from the New York Attorney General's office regarding their use of "secondary" wholesalers as a source of pharmaceuticals

GSK Wellbutrin XL Launch Not Affected By Lost Shipment, Biovail Says

GlaxoSmithKline's ongoing launch of Wellbutrin XL will not be affected by the loss of a product shipment from Biovail's manufacturing facility, Biovail assured analysts during an Oct. 3 teleconference

Table

View full table

Tags:
Latest Headlines

Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification

US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios

FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says

New EU Filings

See All
UsernamePublicRestriction

Register

PS042483

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By